![PDF) Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan | Hoda Atef - Academia.edu PDF) Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan | Hoda Atef - Academia.edu](https://0.academia-photos.com/attachment_thumbnails/67747136/mini_magick20210625-7756-f5myfh.png?1624660415)
PDF) Effect of Spironolactone on Diabetic Nephropathy Compared to the Combination of Spironolactone and Losartan | Hoda Atef - Academia.edu
![Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial - The Lancet Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial - The Lancet](https://www.thelancet.com/cms/attachment/92c78bdc-c776-4547-8c9f-25d568de4172/gr1_lrg.gif)
Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial - The Lancet
![Clinical perspective—evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes - Kidney International Supplements Clinical perspective—evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes - Kidney International Supplements](https://www.kisupplements.org/cms/asset/9128561d-21e4-4b33-b5c4-c55428eeea69/fx1.jpg)
Clinical perspective—evolving evidence of mineralocorticoid receptor antagonists in patients with chronic kidney disease and type 2 diabetes - Kidney International Supplements
![Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension | Journal of Human Hypertension Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension | Journal of Human Hypertension](https://media.springernature.com/w300/springer-static/image/art%3A10.1038%2Fjhh.2014.27/MediaObjects/41371_2015_Article_BFjhh201427_Figa_HTML.jpg)
Low-dose spironolactone reduces plasma fibulin-1 levels in patients with type 2 diabetes and resistant hypertension | Journal of Human Hypertension
Spironolactone reduces brachial pulse wave velocity and PIIINP levels in hypertensive diabetic patients
![Frontiers | Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling Frontiers | Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling](https://www.frontiersin.org/files/Articles/149990/fphys-06-00269-r2/image_m/fphys-06-00269-g007.jpg)
Frontiers | Spironolactone treatment attenuates vascular dysfunction in type 2 diabetic mice by decreasing oxidative stress and restoring NO/GC signaling
![Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial - The Lancet Diabetes & Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial - The Lancet Diabetes &](https://www.thelancet.com/cms/attachment/e8276df5-2f9e-4e37-bd07-e313ed200bf4/gr1.gif)
Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial - The Lancet Diabetes &
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril a
![Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes - ScienceDirect Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1931524420300736-gr5.jpg)
Baseline urinary metabolites predict albuminuria response to spironolactone in type 2 diabetes - ScienceDirect
Beneficial Effects of Adding Spironolactone to Recommended Antihypertensive Treatment in Diabetic Nephropathy
Treating resistant hypertension in type 2 diabetes: a role for spironolactone? - Adrian G Stanley, Philip Swales, Herbert Thurston, Bryan Williams, 2006
Effect of low-dose spironolactone on resistant hypertension in type 2 diabetes mellitus: a randomized controlled trial in a sub-
![Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy - ScienceDirect Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0002962918300521-gr1.jpg)
Effects of Different Doses of Irbesartan Combined With Spironolactone on Urinary Albumin Excretion Rate in Elderly Patients With Early Type 2 Diabetic Nephropathy - ScienceDirect
![Effect of spironolactone and placebo on prostasin in plasma and urine... | Download Scientific Diagram Effect of spironolactone and placebo on prostasin in plasma and urine... | Download Scientific Diagram](https://www.researchgate.net/publication/313971225/figure/fig1/AS:941429144702978@1601465607165/Effect-of-spironolactone-and-placebo-on-prostasin-in-plasma-and-urine-from-patients.gif)
Effect of spironolactone and placebo on prostasin in plasma and urine... | Download Scientific Diagram
![The Effects of Adding Spironolactone to ACEI or ARB on Proteinuria in Type 2 Diabetes | Semantic Scholar The Effects of Adding Spironolactone to ACEI or ARB on Proteinuria in Type 2 Diabetes | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/da50a225b14f6db26c5f890750fd4e30743f015c/5-Figure3-1.png)
The Effects of Adding Spironolactone to ACEI or ARB on Proteinuria in Type 2 Diabetes | Semantic Scholar
![Effect of Spironolactone Therapy on Albuminuria in Patients with Type 2 Diabetes Treated with Angiotensin-Converting Enzyme Inhibitors - Endocrine Practice Effect of Spironolactone Therapy on Albuminuria in Patients with Type 2 Diabetes Treated with Angiotensin-Converting Enzyme Inhibitors - Endocrine Practice](https://www.endocrinepractice.org/cms/asset/78d3235b-871c-49f9-854f-ffc147b72a22/gr1.jpg)
Effect of Spironolactone Therapy on Albuminuria in Patients with Type 2 Diabetes Treated with Angiotensin-Converting Enzyme Inhibitors - Endocrine Practice
![JCM | Free Full-Text | Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease JCM | Free Full-Text | Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease](https://pub.mdpi-res.com/jcm/jcm-07-00459/article_deploy/html/images/jcm-07-00459-g001.png?1570727050)
JCM | Free Full-Text | Long-Term Effects of Spironolactone on Kidney Function and Hyperkalemia-Associated Hospitalization in Patients with Chronic Kidney Disease
![Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users | BMC Nephrology | Full Text Disease characteristics and outcomes in patients with chronic kidney disease and type 2 diabetes: a matched cohort study of spironolactone users and non-users | BMC Nephrology | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12882-020-01719-7/MediaObjects/12882_2020_1719_Fig2_HTML.png)